Revvity to Sell China Immunodiagnostics Assets

Revvity announced plans to divest its China Immunodiagnostics business for $200 million. The business being sold is part of the Diagnostics segment, which accounted for $1,424,947 (FY2025, $ in thousands) or 33.3% of consolidated revenue. The announcement is a discrete corporate action affecting Revvity’s Diagnostics footprint in China; transaction timing, regulatory approvals, buyer identity and intended use of proceeds were not disclosed in the provided materials. For investors, the key near-term fact is the sale price ($200M) and the segmental placement of the asset. The Diagnostics segment represented one-third of FY2025 revenue, while Life Sciences generated roughly two-thirds ($2,856,051 in thousands). Any material impact on revenue, operating income or margins will depend on the relative contribution of the China Immunodiagnostics assets to the broader Diagnostics totals and on post-closing arrangements not specified here.

FY2025 revenue by business unit (reported in thousands) shows Revvity’s Life Sciences revenue at 2,856,051 (66.7% of total) and Diagnostics at 1,424,947 (33.3%). Total reported revenue for FY2025 was 4,280,998 (in thousands). The Diagnostics segment contains immunodiagnostics activities; a $200M divestiture of China immunodiagnostics assets represents a transaction against a segment that generated approximately one-third of consolidated revenue in FY2025. The company's disclosed financial profile also notes long-term gross debt of $3.24 billion and $86 million of interest paid in FY2025. Debt covenants and leverage constraints were identified as risks in the company filings; any asset sale could interact with cash flow, debt service and covenant metrics, but no allocation of proceeds or covenant effects is provided in the supplied information.

Revvity’s stated strategy in its filings emphasizes strengthening key markets, accelerating innovation, talent retention, and growth in Life Sciences and Diagnostics through strategic acquisitions and licensing. The planned sale of China Immunodiagnostics assets for $200M sits within that strategic context as a corporate portfolio action, but the provided materials do not specify whether the divestiture aligns with a targeted refocus on core products, geographic optimization, or balance sheet objectives. From the company’s risk disclosures and moat assessment: Revvity derives competitive advantage from execution in drug discovery workflows and immunodiagnostics, but the filings note no clear sustainable structural moat. Risks relevant to a diagnostics divestiture include regulatory requirements for diagnostics in multiple jurisdictions (FDA/EU rules, data privacy), product liability exposure, macroeconomic factors (FX, tariffs, inflation), and cybersecurity oversight. Patent portfolios (e.g., base editing, CHOSOURCE) and execution capabilities drive innovation, but patent expirations and competitive in-licensing present commoditization risk. Investors should weigh these documented risks alongside any future disclosures about the buyer, deal structure, regulatory approvals and the asset’s contribution to historic Diagnostics revenue.